Company news

Amneal Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amneal Reports First Quarter 2021 Financial Results

May 6, 2021

Amneal to Report First Quarter 2021 Results on May 7, 2021

April 14, 2021

Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals

April 4, 2021

Amneal Reports Fourth Quarter and Full Year 2020 Financial Results

February 25, 2021

Amneal Receives Approval for Generic Version of Ortho Evra®

February 25, 2021

Amneal to Report Fourth Quarter & Full Year 2020 Results on February 26, 2021

February 3, 2021

Amneal to Acquire Substantially All of Kashiv Specialty Pharmaceuticals

January 11, 2021

Amneal Launches Generic Abiraterone Acetate Tablets, USP, 500 mg, Following ANDA Approval by FDA

January 7, 2021

Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%

November 10, 2020

Amneal Reports Third Quarter 2020 Financial Results

November 5, 2020

Amneal to Report Third Quarter 2020 Results on November 6, 2020

October 14, 2020

Amneal & PL Developments Launch Store Brand Program of Over-the-Counter (“OTC”) Diclofenac Sodium Topical Gel, 1%

October 7, 2020

Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%

August 24, 2020

Amneal Reports Second Quarter 2020 Financial Results

August 5, 2020

Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA

July 9, 2020

Amneal to Report Second Quarter 2020 Results on August 6, 2020

July 7, 2020

Amneal Reports First Quarter 2020 Financial Results

May 10, 2020

Amneal to Report First Quarter 2020 Results on May 11, 2020

April 23, 2020

Amneal Launches Generic Butrans® Following ANDA Approval by FDA

April 15, 2020

Amneal Pharmaceuticals Moving to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders

April 14, 2020

Amneal Accelerates Distribution and Production of Hydroxychloroquine Sulfate to Meet Potential Needs of COVID-19 Patients Nationwide

March 19, 2020

Amneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer

March 10, 2020

Amneal Reports Fourth Quarter and Full Year 2019 Financial Results

February 25, 2020

Amneal to Report Fourth Quarter and Full Year 2019 Results on February 26, 2020

January 23, 2020

Amneal Appoints Jeff George, John Kiely and Shlomo Yanai to Board of Directors

December 15, 2019

Amneal Receives Abbreviated New Drug Application Approval for EluRyng™, the First Generic NuvaRing®

December 11, 2019

Amneal to Acquire Majority Interest in AvKARE, Enhancing Access to Growing Federal Healthcare Market

December 9, 2019

Amneal Announces the Approval and Launch of Generic Carafate®

December 2, 2019

Amneal Announces the Approval and Launch of Generic Revatio® for Oral Suspension and Generic Amicar® Tablets

December 1, 2019

Amneal Reports Third Quarter 2019 Financial Results

November 5, 2019

Amneal Enters into a Licensing Agreement with Kashiv BioSciences, LLC to Develop and Commercialize K127 for the Treatment of Myasthenia Gravis

November 5, 2019

← Newer news releases

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 56 decks. Every deck is listed under its year.